| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | FSC231 | CTRPv2 | pan-cancer | AAC | 0.0054 | 0.9 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | 0.0029 | 0.9 |
| mRNA | PDMP | CTRPv2 | pan-cancer | AAC | -0.0027 | 0.9 |
| mRNA | sitagliptin | CTRPv2 | pan-cancer | AAC | -0.0048 | 0.9 |
| mRNA | AZD8055 | CTRPv2 | pan-cancer | AAC | -0.0022 | 0.9 |
| mRNA | dabrafenib | CTRPv2 | pan-cancer | AAC | 0.0028 | 1 |
| mRNA | GW-405833 | CTRPv2 | pan-cancer | AAC | -0.0019 | 1 |
| mRNA | tandutinib | CTRPv2 | pan-cancer | AAC | 0.0016 | 1 |
| mRNA | BRD-A05715709 | CTRPv2 | pan-cancer | AAC | -0.0025 | 1 |
| mRNA | BRD-K48477130 | CTRPv2 | pan-cancer | AAC | -0.0024 | 1 |